Columvi Európska únia - slovenčina - EMA (European Medicines Agency)

columvi

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastické činidlá - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Tepkinly Európska únia - slovenčina - EMA (European Medicines Agency)

tepkinly

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastické činidlá - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Talvey Európska únia - slovenčina - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - viacnásobný myelóm - antineoplastické činidlá - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Lunsumio Európska únia - slovenčina - EMA (European Medicines Agency)

lunsumio

roche registration gmbh - mosunetuzumab - lymfóm, folikulárny - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Tecvayli Európska únia - slovenčina - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - viacnásobný myelóm - antineoplastické činidlá - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Spevigo Európska únia - slovenčina - EMA (European Medicines Agency)

spevigo

boehringer ingelheim international gmbh - spesolimab - svrab - imunosupresíva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Kimmtrak Európska únia - slovenčina - EMA (European Medicines Agency)

kimmtrak

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastické činidlá - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.